MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING
***
Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants
“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“
A Partner of the Institute of Medical Business Advisors , Inc.
http://www.MedicalBusinessAdvisors.com
SPONSORED BY: Marcinko & Associates, Inc.
***
http://www.MarcinkoAssociates.com
Daily Update Provided By Staff Reporters Since 2007. How May We Serve You? |
© Copyright Institute of Medical Business Advisors, Inc. All rights reserved. 2024 |
REFER A COLLEAGUE: MarcinkoAdvisors@msn.com
SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/
ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z
***
Walgreens has released its own brand of naloxone, a medication that reverses the effects of an opioid overdose. Available online now, Walgreens Brand Naloxone HCl Nasal Spray comes with two doses for $34.99, about $10 cheaper than the name-brand version, Narcan. The over-the-counter medication will also be available in stores by the end of May in the pain aisle, according to a press release, making the life-saving nasal spray more accessible.
***
Here’s where the major benchmarks ended:
- The S&P 500 index rose 6.17 points (0.1%) to 5,303.27, up 1.5% for the week; the Dow Jones Industrial Average gained 134.21 points (0.3%) to 40,003.59, up 1.2% for the week; the NASDAQ Composite® ($COMP) lost 12.35 points (0.1%) to 16,685.97, up 2.1% for the week.
- The 10-year Treasury note yield (TNX) rose more than 4 basis points to 4.42%, down about 8 basis points for the week.
- The CBOE Volatility Index® (VIX) fell 0.43 to 11.99.
Among major companies, Nvidia (NVDA) dropped 2% Friday but still posted a 2.9% advance for the week ahead of the semiconductor leader’s quarterly earnings Wednesday. Among sectors, energy shares led gainers behind a 1% jump in WTI Crude Oil (/CL) futures. The small-cap Russell 2000® Index (RUT) ended little changed but still gained 1.7% for the week.
CITE: https://www.r2library.com/Resource
Fraudulent research papers have cost scientific journal publishers millions in lost revenue. (the Wall Street Journal)
CITE: https://tinyurl.com/2h47urt5
The 10 Top Causes of Adult Death in the U.S.A.
1. Heart disease 267.2* 2. Cancer 142.3 3. Unintentional injuries 64.0 4. COVID-19 44.5 5. Stroke 39.5 6. Chronic lower respiratory disease 34.3 7. Alzheimer disease 28.9 8. Diabetes 24.1 9 Kidney disease 13.8 10. Chronic liver disease and cirrhosis 13.8 Deaths per 100,000 population.
Source: Jeffrey Bendix, Medical Economics [5/15/24]
CITE: https://tinyurl.com/tj8smmes
COMMENTS APPRECIATED
PLEASE SUBSCRIBE: MarcinkoAdvisors@msns.com
Thank You
***
***
***
***
EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf
***
Filed under: "Ask-an-Advisor", Breaking News, Drugs and Pharma, Ethics, Experts Invited, Financial Planning, Health Economics, Health Insurance, Healthcare Finance, Information Technology, Investing, LifeStyle, Marcinko Associates, Recommended Books, Sponsors, Touring with Marcinko, Uncategorized | Tagged: causes of death, CBOE, crude, DJIA, fraudulent research papers, Marcinko, Medical Economics, naloxone, narcan, NASDAQ, Nvidia, Palantir, S&P 500, textbooks, top 10 causes death USA, VIX, walgreens, WSJ | Leave a comment »